


CORRECTION

Open Access



Correction to: Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience

Shinya Tsuboi^{1,2}, Tatsuya Hayama^{1,2}, Katsuhiko Miura^{2,3*} , Akihiro Uchiike^{1,2}, Daisuke Tsutsumi¹, Takashi Yamauchi^{1,2}, Yoshihiro Hatta³ and Susumu Ootsuka¹

Correction to: *J Pharm Health Care Sci* 9, 2 (2023)

<https://doi.org/10.1186/s40780-022-00272-9>

After publication of the original article [1] the authors found an error in the analysis. According to the univariate logistic regression analysis findings summarized in original Table 1, the item “Type of chemotherapy (adjuvant chemotherapy vs. chemotherapy alone)” mentioned odds ratio (OR) of 2.93, with a 95% confidence interval (CI) of 1.29–6.62 and p-value of 0.010.

According to the statistical method used, this item should be included in multivariate analysis. However, the results for this clinical factor in the multivariate analysis were blank. The correct version of Table 1 is included in this correction article.

Accordingly, the corrected OR for younger age (<55 years) related to pegfilgrastim-induced bone pain is 3.68 (95% CI 1.52–8.90, $p=0.003$). Owing to the minimum alterations in OR and p-values in multivariate analysis, the authors believe that this correction does not significantly impact the study results.

The online version of the original article can be found at <https://doi.org/10.1186/s40780-022-00272-9>.

*Correspondence:

Katsuhiko Miura
miura.katsuhiko@nihon-u.ac.jp

¹Department of Pharmacy, Nihon University Itabashi Hospital, 30-1 Oyaguchikamicho, Itabashi city, Tokyo 173-8610, Japan

²Tumor Center, Nihon University Itabashi Hospital, 30-1 Oyaguchikamicho, Itabashi city, Tokyo 173-8610, Japan

³Department of Medicine, Division of Hematology and Rheumatology, Nihon University School of Medicine, 30-1 Oyaguchikamicho, Itabashi city, Tokyo 173-8610, Japan



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 1 Logistic regression analyses for the incidence of pegfilgrastim-induced bone pain

	PIBP incidence N (%)	Univariate analysis			Multivariate analysis		
		OR	95% CI	p-value*	OR	95% CI	p-value*
Sex							
Male	2 (3)	Reference			Reference		
Female	28 (12)	5.54	1.29–23.83	0.021	1.99	0.36–11.0	0.413
Age							
<55 years	21 (20)	5.31	2.32–12.07	>0.001	3.68	1.52–8.90	0.003
≥55 years	9 (5)	Reference			Reference		
Pre-existing osteoporosis							
Yes	0	NA			-		
No	30 (10)	NA			-		
Type of tumor							
Solid cancers	27 (14)	5.39	1.60–18.21	0.007	2.73	0.60–12.43	0.183
Hematologic cancers	3 (3)	Reference			Reference		
Bone metastasis							
Present	3 (10)	0.71	0.21–4.84	0.596	-		
Absent	27 (10)	Reference			-		
Opioids							
Yes	1 (8)	0.79	0.09–6.02	0.784	-		
No	29 (10)	Reference			-		
NSAIDs							
Yes	2 (13)	1.33	0.28–6.16	0.714	-		
No	28 (10)	Reference			-		
Prior chemotherapy							
Yes	4 (14)	1.61	0.52–4.99	0.412	-		
No	26 (9)	Reference			-		
Type of chemotherapy							
Adjuvant chemotherapy	21 (14)	2.93	1.29–6.62	0.010	1.14	0.40–3.23	0.804
Chemotherapy alone	9 (6)	Reference			Reference		
Type of prophylaxis							
Primary	23 (9)	1.48	0.60–3.64	0.410			
Secondary	7 (13)	Reference					
Pegfilgrastim injection							
Day 2 or 3	10 (8)	Reference			-		
Days 4–7	20 (11)	1.53	0.69–3.38	0.298	-		

NA, not applicable; OR, odds ratio; CI, confidence interval; PIBP, pegfilgrastim-induced bone pain; NSAIDs, non-steroidal anti-inflammatory drugs.

* P-values were calculated by logistic regression analyses.

Published online: 14 April 2023

myelosuppressive chemotherapy: a realworld experience. *J Pharm Heal Care Sci.* 2023;9:1–5. <https://doi.org/10.1186/s40780-022-00272-9>.

References

1. Tsuboi S, Hayama T, Miura K, Uchiike A, Tsutsumi D, Yamauchi T, et al. Higher incidence of pegfilgrastim induced bone pain in younger patients receiving

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.